Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02611063 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant
A Phase 1 study, sponsored by Stefanie Sarantopoulos, MD, PhD..
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02611063 is a Phase 1 study that has completed, run by Stefanie Sarantopoulos, MD, PhD.. The registered enrollment target is 22 participants.
The verdict
NCT02611063, a Phase 1 study, has completed, sponsored by Stefanie Sarantopoulos, MD, PhD..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether fostamatinib, a drug that blocks activated B cells will be effective in preventing and treating chronic graft vs host disease (cGVHD) after allogeneic stem cell transplant. Activated B cells may play a role in development of cGVHD. Inhibiting the B cell activation using fostamatinib after allogeneic stem cell transplant may prevent the development of cGVHD.
Interventions
- DRUG fostamatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-01 |
| Est. Completion | 2022-02-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02611063
The ClinicalTrials.gov registry entry for NCT02611063 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stefanie Sarantopoulos, MD, PhD., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fostamatinib is the first listed.
NCT02611063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02611063 about?
NCT02611063 is a clinical study titled "Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant". The purpose of this study is to evaluate whether fostamatinib, a drug that blocks activated B cells will be effective in preventing and treating chronic graft vs host disease (cGVHD) after allogeneic stem cell transplant. Activated B cells may play a role in development of cGVHD. Inhibiting the B ce...
What is the current status of trial NCT02611063?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2016-01. Estimated completion is 2022-02-22.
What interventions are being tested in trial NCT02611063?
The interventions under investigation include: fostamatinib (DRUG).
Who is sponsoring clinical trial NCT02611063?
This trial is sponsored by Stefanie Sarantopoulos, MD, PhD., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.